Background and Objective: Evidence indicates that genetic factors may be involved in the risk of ischemic stroke (IS). The aim of this study was to assess the effect of genetic polymorphisms located in exons or untranslated regions of MTHFR as well as FV genes on ischemic stroke. Materials and Methods: In this case-control study, 106 patients with IS and 157 healthy volunteers (age <50 years) were genotyped for MTHFR C677T, A1298C, C2572A and C4869G, FVL, and prothrombin G20210A polymorphisms. Results: The MTHFR 677CT genotype was more frequent in patients and increased risk of IS with Odds Ratio = 1.9. The MTHFR A1298C and C2572A polymorphisms were not associated with IS in dominant and recessive models. Our findings showed a significant decrease in the MTHFR 4869CG genotype in IS patients, and this variant was associated with a decreased risk of IS in the dominant model. The CAAT haplotype was associated with increased risk, and the GAAC haplotype was associated with decreased risk of IS compared to other haplotypes. There was no relation between FVL G1691A polymorphism and IS risk. Conclusions: The present study showed that the MTHFR 677CT genotype was more frequent and the MTHFR 4869CG genotype was less frequent in young IS patients.

IntroductionHepatopulmonary syndrome is commonly seen in the patients with chronic liver disease. Acute liver diseases are rarely associated with HPS. We have reported here a case of Transient HPS caused by Epstein-Barr virus hepatitis.Case reportThe patient was a 31 years old man that came to hospital due to RUQ pain and yellowish skin. In examination the patient was tachypnic and O2 saturation was 71% with prominent JVP. ver enzyme and bilirubin were high. All viral hepatitis was negative except anti viral capsid antigen-antibody of EBV. In Blood gas PaO2 was 54 mmHg, O2 saturation 73% and alveolar-arterial gradient was 18 mmHg. Stress Echocardiography with saline injection reported pulmonary arterial pressure 32 cmHg with delayed opacification of left atrium.Conclusiontransient HPS can be manifestation in the acute hepatitis caused by EBV infection.

The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel ... [3] Defining autoimmune hemolytic anemia: a systematic review of the terminology ... [4] Durch β-Thalassaemia minor maskierte autoimmune perniziöse ... [5] How I treat transfusional iron ... [6] Harrison's principles of internal ... [7] Pathophysiology of ... [8] A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients ... [9] Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects ... [10] Safety, tolerability, and pharmacokinetics of ICL670, a new orally active ironchelating agent in patients with transfusion-dependent iron overload ... [11] Current approach to iron chelation ... [12] Cross-talk between available guidelines for the management of patients with ... [13] Light and shadows in the iron chelation treatment ... [14] Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with ... [15] Accuracy of magnetic resonance imaging in diagnosis of liver iron overload ... [16] Iron chelation in thalassemia ... [17] Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia ... [18] Efficacy of deferasirox in reducing and preventing cardiac iron overload in ... [19] Iron overload in thalassemia and related conditions: therapeutic goals and assessment of ... [20] Long-term efficacy of oral deferiprone in management of iron overload in ... [21] Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients ... [22] Deferiprone versus deferoxamine in patients with thalassemia major ... [23] Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone ... [24] Comparing the efficacy of Dexeroyx (Osveral) and Deferoxamine ... [25] Survival and complications in patients with thalassemia major treated ...

Background & aim: Acute rheumatic fever is an autoimmune disease that mainly affects the large joints. Early treatment of a throat infection following group A streptococcus prevents of acute rheumatic fever. Given the low prevalence of the disease, especially in a situation where there is excessive use of antibiotics in Iran, this study intends to report a patient with acute rheumatic fever with mild criteria.Case report: the patient was a 14-year-old male that came to the internal medicine clinic due to weakness and joint pain. The patient had pain in the joints of the wrists and ankles, as well as the knees which was migratory in the patient. He had a history of fever and sore throat a month before the visit. The patient did not describe the skin lesion. On examination, the patient had vital signs of BP: 100/60 mmhg, PR: 90 / min, RR: 25, and T: 37.7. The throat examination was slightly erythematous, and without exudates, the cardiac examination was tachycardia without murmur. On examination of the joints, only the left knee joint had redness, and it was warm to the touch. In the laboratory tests, ASO: 400, ESR: 94 and CRP: 76 were. The patient's chest x ray, ECG, and echocardiogram were normal. Based on the symptoms and laboratory tests in Jones criteria, the diagnosis of ARF was confirmed. Then, the initial treatment, naproxen and co-amoxiclav was started, and explained for the patient to receive injection of penicillin benzathine once a month until the age of 21. Conclusion:Acute rheumatic fever should be considered as part of the differential diagnosis of polyarthritis in the young patients, so that, if present, with appropriate treatment and prophylaxis, we can to able reduce the social costs from rheumatic heart disease.